|
(Health-NewsWire.Net, July 21, 2015 ) Psoriatic Arthritis - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Psoriatic Arthritis - Pipeline Review, H1 2015” which provides an overview of the Arthritis therapeutic pipeline.
This report gives thorough data on the helpful advancement for Psoriatic Arthritis, complete with relative investigation at different stages, therapeutics evaluation by medication target, component of activity (MoA), course of organization (RoA) and particle sort, alongside most recent overhauls, and included news and press discharges. It additionally audits key players included in the restorative advancement for Psoriatic Arthritis and extraordinary elements on late-stage and stopped undertakings.
The report upgrades choice making capacities and help to make powerful counter methodologies to increase game changer. It fortifies R&D pipelines by distinguishing new targets and MOAs to create first-in-class and best-in-class items.
Complete report on H1, 2015 Pipeline Review of “Psoriatic Arthritis” addition with 50 market data tables and 15 figures, spread across 190 pages is http://www.rnrmarketresearch.com/psoriatic-arthritis-pipeline-review-h1-2015-market-report.html .
This report highlights investigational medications from crosswise over globe covering more than 20 treatment territories and about 3,000 signs. The report is assembled utilizing information and data sourced from Global Markets Direct's exclusive databases, Company/University sites, SEC filings, speculator presentations and highlighted press discharges from organization/college destinations and industry-particular outsider sources, set up together by Global Markets Direct's group. Medication profiles/records highlighted in the report experiences occasional updation taking after a stringent arrangement of procedures that guarantees that every one of the profiles are upgraded with the most recent arrangement of data. Also, procedures including live news & arrangements following, program based ready box and clinical trials registries following guarantee that the latest advancements are caught on an ongoing premise.
Drugs Profile Discussed in this Research :
abatacept (recombinant), AbGn-168H, ABT-122, adalimumab biosimilar, anakinra (recombinant) , apremilast, bimekizumab, brodalumab, clazakizumab, COVA-322, dalazatide, etanercept biosimilar, golimumab, golimumab biosimilar, guselkumab, IBI-303, IBPM-004AM, IBPM-005IX, infliximab biosimilar, INV-17, itolizumab, ixekizumab, Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis, secukinumab and tofacitinib.
Companies Discussed/Mentioned in this Research:
AbbVie Inc., AbGenomics International, Inc., Alder Biopharmaceuticals Inc., Amgen Inc., Avesthagen Limited, Biocon Limited, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Inc., Coherus BioSciences, Inc., Covagen AG, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Genor BioPharma Co., Ltd., Inbiopro Solutions Pvt. Ltd., Innovent Biologics, Inc., Johnson & Johnson, Kineta, Inc., Mabion SA, Momenta Pharmaceuticals, Inc., Novartis AG, Oncobiologics, Inc., Panacea Biotec Limited, Pfizer Inc., Sandoz International GmbH, Swedish Orphan Biovitrum AB, Therapeutic Proteins International, LLC and UCB S.A.
Inquire for discount on this report http://www.rnrmarketresearch.com/contacts/discount?rname=394571 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Arthritis therapeutics Market
Since the invention of user friendly gadgets, humans have learned to become lazy and make the gizmos responsible for both good and bad. Even the irritable pollution is made accountable for interfering in normal features of a humanoid body. But blaming others is just not the solution of any problem. It is now that Arthritis therapeutics enters actively in to the scenario.
Fast growing drug market with ample choices in front of the therapists makes this pharmaceutical industry reach its desired height of success. In fact with more number of people suffering from rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), surely accelerates their growth in this sector. Globally the pharmaceutical companies are now ready to make more investments as higher returns are for sure.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
